Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP1135291.RApbsVbv1102UVDjhgaD4v-AIi6PumiSbiMJF1aMCubu4130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP1135291.RApbsVbv1102UVDjhgaD4v-AIi6PumiSbiMJF1aMCubu4130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP1135291.RApbsVbv1102UVDjhgaD4v-AIi6PumiSbiMJF1aMCubu4130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP1135291.RApbsVbv1102UVDjhgaD4v-AIi6PumiSbiMJF1aMCubu4130_provenance.
- NP1135291.RApbsVbv1102UVDjhgaD4v-AIi6PumiSbiMJF1aMCubu4130_assertion description "[On the basis of preclinical data suggesting synergy of HER2 inhibition and mTOR inhibition in breast and lung cancer models, we conducted a phase I combination study of neratinib, a small-molecule irreversible pan-HER tyrosine kinase inhibitor, and temsirolimus, an mTOR inhibitor, in patients with advanced solid tumors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1135291.RApbsVbv1102UVDjhgaD4v-AIi6PumiSbiMJF1aMCubu4130_provenance.
- NP1135291.RApbsVbv1102UVDjhgaD4v-AIi6PumiSbiMJF1aMCubu4130_assertion evidence source_evidence_literature NP1135291.RApbsVbv1102UVDjhgaD4v-AIi6PumiSbiMJF1aMCubu4130_provenance.
- NP1135291.RApbsVbv1102UVDjhgaD4v-AIi6PumiSbiMJF1aMCubu4130_assertion SIO_000772 24323026 NP1135291.RApbsVbv1102UVDjhgaD4v-AIi6PumiSbiMJF1aMCubu4130_provenance.
- NP1135291.RApbsVbv1102UVDjhgaD4v-AIi6PumiSbiMJF1aMCubu4130_assertion wasDerivedFrom befree-2016 NP1135291.RApbsVbv1102UVDjhgaD4v-AIi6PumiSbiMJF1aMCubu4130_provenance.
- NP1135291.RApbsVbv1102UVDjhgaD4v-AIi6PumiSbiMJF1aMCubu4130_assertion wasGeneratedBy ECO_0000203 NP1135291.RApbsVbv1102UVDjhgaD4v-AIi6PumiSbiMJF1aMCubu4130_provenance.
- befree-2016 importedOn "2016-02-19" NP1135291.RApbsVbv1102UVDjhgaD4v-AIi6PumiSbiMJF1aMCubu4130_provenance.